Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in Complement 3 Glomerulopathy
NCT04817618Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jul 2021
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of Iptacopan in Complement 3 glomerulopathy (C3G), sponsored by Novartis. Started Jul 2021; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on NCT04817618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04817618.